股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 備註： ...

致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 備註 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京綠竹生物技術股份有限公司 呈交日期: 2025年11月3日 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RM ...

Core Viewpoint - The Phase I clinical trial of LZ901 vaccine conducted in the United States has been successfully completed, demonstrating good safety and immunogenicity in both high-dose and low-dose groups compared to the placebo group, laying the foundation for subsequent clinical research [1] Group 1: Clinical Trial Results - The Phase I clinical trial primarily aimed to verify the safety of the vaccine, with only the low-dose group showing mild adverse reactions related to the vaccine at a rate of 4.35%, while no adverse reactions were reported in the high-dose and placebo groups [1] - Both high-dose and low-dose groups of the LZ901 vaccine exhibited good safety and immunogenicity compared to the placebo group [1] Group 2: Product Development - LZ901 is a self-developed recombinant shingles vaccine by the company, targeting the prevention of shingles and related complications in adults aged 40 and above [1] - The Phase III clinical trial of LZ901 in China has met its clinical preset goals and achieved expected clinical results [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under evaluation [1]

Core Viewpoint - The clinical trial for LZ901 vaccine conducted in the United States has successfully completed Phase I, demonstrating good safety and immunogenicity in both high and low dose groups compared to the placebo group, laying the groundwork for further clinical research [1] Group 1: Clinical Trial Results - The Phase I clinical trial of LZ901 vaccine showed good safety and immunogenicity in both high and low dose groups compared to the placebo group [1] - The primary objective of the trial was to verify the vaccine's safety, with only the low dose group experiencing mild adverse reactions (4.35%), while no adverse reactions were reported in the high dose and placebo groups [1] Group 2: Product Development - LZ901 is a recombinant shingles vaccine developed by the company, aimed at preventing shingles and related complications in adults aged 40 and above [1] - The vaccine has achieved its clinical preset goals in a Phase III trial conducted in China and has obtained expected clinical results [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under evaluation [1]

Group 1 - The core product LZ901 is a recombinant vaccine developed by the company to prevent shingles and related complications in adults aged 40 and above [2] - The Phase I clinical trial of LZ901 in the United States was successfully completed in September 2025, demonstrating good safety and immunogenicity in both high-dose and low-dose groups compared to the placebo group [1] - The Phase I clinical trial began in February 2023, involving 66 healthy participants aged 50 to 70, and was designed as a randomized, double-blind, placebo-controlled, and dose-escalation study [1] Group 2 - The primary objective of the Phase I clinical trial was to verify the vaccine's safety, with only the low-dose group showing mild adverse reactions (4.35%), while no adverse reactions were reported in the high-dose and placebo groups [1] - LZ901 has achieved its clinical preset goals in the Phase III clinical trial in China and has received acceptance for its biological product license application from the National Medical Products Administration of China, which is currently under evaluation [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致的任何損失承擔任何責任。 Beijing Luzhu Biotechnology Co., Ltd. 北京綠竹生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2480） 香港聯合交易所有限公司證券上市規則第18A.05條規定的警示聲明：本公司無法 保證LZ901最終將成功開發及營銷。本公司股東及有意投資者於買賣本公司股份 時務請審慎行事。 關於於美國進行的I期臨床試驗 於美國進行的LZ901的I期臨床試驗於2023年2月開始，為一項隨機、雙盲、安慰 劑對照及劑量遞增研究，旨在評估LZ901在50至70歲健康受試者中的安全性及耐 受性。於美國進行的LZ901的I期臨床試驗合共招募66名受試者。 根據於美國進行的LZ901的I期臨床試驗結果，LZ901疫苗高劑量組和低劑量組較 安慰劑組而言，均表現出良好的安全性和免疫原性。本次臨床試驗主要研究目標 為驗證疫苗的安全性，其中僅LZ901疫苗低劑量組出現與 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02480 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 202,449,032 | RMB | | 1 RMB | | 202,449,032 | 本月底法定/註冊股本總額： RMB 202,449,032 備註： 因本公司是於中華人民共和國註冊成立的股份有限公司，「法定股本」之概念不 ...

Core Viewpoint - The company has appointed Ms. Peng Ling as the Vice General Manager, who will be responsible for quality research, quality control, and quality assurance across various projects [1] Group 1 - Ms. Peng Ling has been serving as an Executive Director and Vice Chairman prior to her new appointment [1] - The role of Vice General Manager will focus on enhancing the quality management processes within the company [1]

Core Viewpoint - Green Bamboo Bio-B (02480.HK) announced the appointment of Peng Ling as the Deputy General Manager, who will focus on quality research, quality control, and quality assurance for the group's projects [1] Group 1 - The company has appointed Peng Ling as the Deputy General Manager [1] - Peng Ling will be responsible for overseeing quality-related aspects of the company's projects [1]